Life sciences news
-
Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study
Tuesday October 20th 2020
Read more
-
Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
Friday October 16th 2020
Read more
-
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
Wednesday October 14th 2020
Read more
-
Phase 2B/3 Trial shows efficacy of Filgotinib for the induction and maintenance of remission in moderately and severely active Ulcerative Colitis
Tuesday October 13th 2020
Read more
-
argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial
Monday October 5th 2020
Read more
-
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
Wednesday September 30th 2020
Read more
-
Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC
Tuesday September 29th 2020
Read more
-
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
Thursday September 24th 2020
Read more
-
Become a flanders.bio member
Your news here?
-
Camel-IDS enters next stage with name change to PRECIRIX® and IND approval for CAM-H2 Phase I/II study
Tuesday September 22nd 2020
Read more
-
Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients
Friday September 11th 2020
Read more
-
Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)
Tuesday September 1st 2020
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
